Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 4/20 | 0.40 |
| ▸ | NOS1 | P29475 | 4/20 | 0.40 |
| ▸ | NOS2 | P35228 | 4/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128592 | 0.97 | — | — | |
| SCHEMBL9255497 | 0.94 | CYP1A2 (0.64) | CYP1A2CA1CA2CA4NOS3 | |
| SCHEMBL7738781 | 0.94 | CYP1A2 (0.70) | CYP1A2CA1CA2CA4NOS3 | |
| SCHEMBL3633846 | 0.94 | CYP1A2 (0.70) | CYP1A2CA1CA2CA4NOS3 | |
| SCHEMBL128915 | 0.94 | — | — | |
| SCHEMBL905661 | 0.94 | CYP1A2 (0.70) | CYP1A2CA1CA2CA4NOS3 | |
| SCHEMBL97288 | 0.94 | CYP1A2 (0.70) | CYP1A2CA1CA2CA4NOS3 | |
| SCHEMBL11726232 | 0.94 | CYP1A2 (0.70) | CYP1A2CA1CA2CA4NOS3 | |
| SCHEMBL7741556 | 0.94 | CYP1A2 (0.70) | CYP1A2CA1CA2CA4NOS3 | |
| Ammonia Solution, Strong SCHEMBL11353604 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981846-B1 | Producing cyclic fuels from conjugated diene | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2021-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981846-B1 | Producing cyclic fuels from conjugated diene | FDFT1, PC, NDUFS8 | CYP1A2 289/4885CA1 1468/4885CA2 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.